Fly News Breaks for September 18, 2017
NBRV
Sep 18, 2017 | 13:15 EDT
SunTrust analyst Edward Nash raised his price target for Nabriva Therapeutics to $24 saying this morning's data verify lefamulin as a novel antibiotic for community acquired bacterial pneumonia. The analyst keeps a Buy rating on the shares.
News For NBRV From the Last 2 Days
There are no results for your query NBRV